|
|
News Breaks | | | | September 15, 2010 | | 15:04 EDT |  | ARNA | Arena Pharma (ARNA) options active; shares down 12% into FDA vote
Arena Pharmaceuticals (ARNA) is recently down $2.72 to $4.14. ARNA shares sold of 35% on September 14 on the release of the Merida FDA briefing documents. The FDA has a tentative scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of ARNA's lorcaserin New Drug Application, or NDA. Piper reiterated its $10 price target. ARNA call option volume of 219K compares to 102K puts. September 4 straddle is at $2.30, October 4 is at $2.60, January is at $3.10 according to Track Data, suggesting large price movement. | |
|
News For ARNA From The Last 14 Days Check below for free stories on ARNA the last two weeks. |
|
|
| May 17, 2013 | | 11:53 EDT | | ARNA | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
 Subscribe for More Information | | | May 15, 2013 | | 14:03 EDT |  | ARNA | Arena Pharma has positive read through from Eisai forecast, says Piper Jaffray
Subscribe for More Information | | | 06:19 EDT | | ARNA | Arena Pharmaceuticals implied volatility at lower end of index mean range
Subscribe for More Information | | | May 8, 2013 | | 05:52 EDT | | ARNA | Stocks with implied volatility movement; ARNA ANR
Stocks with implied volatility movement; Arena Pharmaceuticals (ARNA), Alpha Natural (ANR) according to IVolatility. | | | May 7, 2013 | | 16:54 EDT |  | ARNA | On The Fly: Closing Wrap
Subscribe for More Information | | | 15:33 EDT |  | ARNA | Arena to receive $65M in milestone payments from Eisai related to Belviq
Subscribe for More Information | | | 14:16 EDT | | ARNA | Arena climbs after DEA takes action on anti-obesity drug
Arena Pharmaceuticals (ARNA) is rallying after the Drug Enforcement Administration determined that the company's anti-obesity drug, lorcaserin, has relatively low potential for abuse. In a note to investors, research firm Piper Jaffray wrote that the DEA's action indicates that lorcaserin will be launched in the U.S. on or around June 7. WHAT'S NEW: The DEA announced in a written statement that it was declaring lorcaserin to be a Schedule IV drug. Schedule IV drugs are defined as drugs with a low potential for abuse and low risk of dependence, according to the Justice Department. In a note to investors, Piper Jaffray analyst Edward Tenthoff predicted that Arena's partner, Eisai, would launch lorcaserin in the U.S. on or around June 7. In addition, the DEA's action will trigger payments of $65M to Arena from Eisai this quarter, according to the analyst. Lorcaserin should generate revenue of $22M this year and $141M next year for Arena, added the analyst, who kept an Overweight rating on the stock. TODAY'S PRICE ACTION: In mid-afternoon trading, Arena gained 85c, or 11.30%, to $8.37. | | | 12:58 EDT | | ARNA | On The Fly: Midday Wrap
Subscribe for More Information | | | 10:43 EDT | | ARNA | DEA places Arena weight loss drug into Schedule IV
The Drug Enforcement Administration issued a final ruling that places the substance lorcaserin into Schedule IV of the Controlled Substances Act. Lorcaserin, a weight-loss drug developed by Arena Pharmaceuticals, is also known by the trade name Belviq. In issuing the ruling, the DEA denied a request to waive a 30-day waiting period for launch following the scheduling. Reference Link | |
|
|
|
|
|
|
